Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

695.82 +0.83 (+0.12%)
Streaming Delayed Price Updated: 2:59 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
57 58 Next >
News headline image
If You Can Only Buy One Biotech Stock, It Better Be One of These 3 Names ↗
These are the best biotech stocks that investors can invest in. That's because they are sector leaders that can make you a millionaire. 
Via InvestorPlace
News headline image
Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List ↗
The World Health Organization (WHO) published the new editions of the Model Lists of Essential Medicines (EML) and Essen 
Via Benzinga
News headline image
The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023 ↗
These three undervalued biotech stocks could have plenty of room to run if their efforts to push out promising pipeline drugs are successful. 
Via InvestorPlace
News headline image
Why Are Kodiak Sciences Shares Trading Lower Today? ↗
Kodiak Sciences Inc (NASDAQ: KOD) shares are tumbling after the company released topline results from three Phase 3 studies of tarcocimab tedromer, a novel antibody biopolymer conjugate, for... 
Via Benzinga
News headline image
Looking Into Regeneron Pharmaceuticals's Recent Short Interest ↗
 
Via Benzinga
News headline image
This Is What Whales Are Betting On Regeneron Pharmaceuticals ↗
 
Via Benzinga
News headline image
$100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity ↗
 
Via Benzinga
News headline image
Is Regeneron Stock a Buy After a Regulatory Blow? ↗
Don't write this company's eulogy too fast. 
Via The Motley Fool
News headline image
Alnylam Says Single Injection Of RNAi Therapy Cuts Alzheimer's-Linked Proteins By 65%, Stock Soars ↗
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) announced updated interim results for the ongoing single ascending dose portion of the Phase 1 study of ALN-APP for Alzheimer's disease and  
Via Benzinga
News headline image
3 Pharma Stocks That AI is Loving in July ↗
Artificial intelligence recommends that these are the three stocks to consider when investing in pharma stocks. 
Via InvestorPlace
News headline image
3 Biotech Stocks to Buy for Long-Term Gains
The biotech sector is one of the most volatile sectors, but here are three biotech stocks that offer opportunities for patient biotech stock investors. 
Via MarketBeat
Topics ETFs Economy
News headline image
Why These 7 Stocks Are the Best Ways to Play Biotech Right Now ↗
With biotech stocks offering myriad viable opportunities irrespective of broader conditions, this sector is worth a closer look. 
Via InvestorPlace
News headline image
Check Out What Whales Are Doing With REGN ↗
 
Via Benzinga
News headline image
Looking Into Regeneron Pharmaceuticals's Recent Short Interest ↗
 
Via Benzinga
News headline image
Why Regeneron Pharmaceuticals Stock Dipped This Week ↗
A key regulatory setback is weighing on the biotech's stock. 
Via The Motley Fool
News headline image
Check Out What Whales Are Doing With REGN ↗
 
Via Benzinga
News headline image
Meta Platforms To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday ↗
Morgan Stanley cut the price target for ArcBest Corporation (NASDAQ: ARCB) from $136 to $125. Morgan Stanley analyst Ravi Shanker maintained an Overweight rating. ArcBest shares fell 3.3% to close at... 
Via Benzinga
News headline image
Is Regeneron's Stock in Trouble After This FDA Rejection? ↗
The company's growth rate has been slowing sharply in recent quarters, and Eylea generates the bulk of its product revenue. 
Via The Motley Fool
News headline image
$1 Billion Deal For Moderna To Expand Product Pipeline in China
Moderna is looking to diversify its falling U.S. product line, a $1 billion investment in China may act as the catalyst pushing the company's valuation higher 
Via MarketBeat
Topics ETFs Economy
News headline image
Biotech Blues: Stay Balanced Through July Earnings Season ↗
Life Science stocks lack momentum so be prepared for rebalancing and rotation shifts. 
Via Talk Markets
News headline image
The 3 Best Biotech Stocks to Buy In July ↗
With these companies fueling sales and earnings with medical innovations and breakthroughs, they may be the best biotech stocks to pick up. 
Via InvestorPlace
News headline image
Stock Market Rally Roars Back Toward Highs; Carnival, Delta, Micron, Nvidia In Focus: Weekly Review ↗
Major indexes rebounded strongly and many stocks flashed buy signals. 
Via Investor's Business Daily
News headline image
Regeneron to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2023
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
What Will Amgen Buy Next? ↗
The biotech could pursue these two budget-friendly targets. 
Via The Motley Fool
News headline image
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
Why Catalent Stock Flopped Today ↗
The company takes the fall for a failed drug application. 
Via The Motley Fool
News headline image
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
Why Regeneron Stock Is Trading Lower Today ↗
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares continue to fall Wednesday after news Tuesday that the FDA issued a Complete Response Letter (CRL) for aflibercept 8 mg Biologics License... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2023 ↗
 
Via Benzinga
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
57 58 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.